SuperworthNexalin Technology price to sales ratio NXL
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- 6.3×
- 3-year median
- 67.9×
- Against its 3-year history
- 0th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 6.3× to 189×
- Peer median
- 0.4×
Nexalin Technology's price to sales ratio is 6.3× as of Oct 23, 2026.
That is below its 3-year median of 67.9×, lower than on 100% of days in the last 3 years.
Over that time it ranged from 6.3× in Oct 2026 to 189× in Mar 2025.
The median for 3 healthcare stocks of a similar size is 0.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 6.3× | 6.3× | 84.7× |
| 2025 | 74.9× | 74.9× | 189× |
| 2024 | 161× | 32.8× | 167× |
Against its peers
Companies in Healthcare nearest Nexalin Technology's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| NXLNexalin Technology | 6.3× |
| OXBROXBRIDGE RE HOLDINGS | 2.8× |
| EDUCEducational Development | 0.4× |
| GTIMGood Times Restaurants | 0.1× |
| Peer median | 0.4× |
Where Nexalin Technology ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Nexalin Technology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.